Intradigm Drops Lead Cancer Rx Candidate As It Focuses on New Targets, Delivery Tech

News of the company’s decision to cease developing its longtime lead drug candidate comes as it adds $2.9 million to its Series B financing round and appoints a new CEO.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories